HansBiomed Corporation (KOSDAQ:042520)

Market Cap	755.85B +618.5%
Revenue (ttm)	100.17B +24.2%
Net Income	-27.44B
EPS	-2,097.10
Shares Out	14.26M
PE Ratio	n/a
Forward PE	49.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	295,097
Average Volume	268,894
Open	53,600
Previous Close	54,500
Day's Range	53,000 - 57,800
52-Week Range	6,180 - 57,800
Beta	2.37
RSI	60.78
Earnings Date	May 15, 2026

About HansBiomed

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product tha...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Employees: 277
• Stock Exchange: KOSDAQ
• Ticker Symbol: 042520

Financial Performance

In fiscal year 2025, HansBiomed's revenue was 89.78 billion, an increase of 10.65% compared to the previous year's 81.14 billion. Losses were -31.34 billion, 333.9% more than in 2024.